Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Sets 'Flexible Pricing' For Kisqali To Compete Against Pfizer's Ibrance

Executive Summary

Novartis has packaged and priced Kisqali – the second CDK4/6 inhibitor approved in the US – to compete with Pfizer's Ibrance, which made the mechanism of action the standard of care in untreated metastatic HR+/HER2- breast cancer.

Advertisement

Related Content

CDK4/6 Inhibitor Market Snapshot: New Drugs Jockey For A Piece Of The Multi-Billion Dollar Pie
Pfizer Japan Looks To Regain Ground Lost After Tough 2016
Pfizer To Compromise On NICE Price For Ibrance?
Pfizer Not Making Pricing Changes, Sees Ways To Work With Trump
J.P. Morgan Notebook Day 1: PCSK9 Face-Off, Teva’s Slowed Growth, Merck’s Keytruda Wins, Lilly’s CDK4/6 Hopes And More
Ibrance Trial Cements CDK4/6 Inhibitors As Standard Of Care In Breast Cancer
Novartis Chief: Good Things Come To Those Who Wait
Novartis CDK4/6 Profile Boosted But Challenge To Pfizer Rival Uncertain
First-Line Breast Cancer Approval Opens The Door For Pfizer’s Palbociclib
Pfizer wins early Ibrance approval in breast cancer

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC098389

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel